Thorough and intensive QTc Studies

Richmond Pharmacology has globally recognised expertise in cardiac safety, intensive ECG studies, cardiology overreading, statistical analysis, reporting and publishing.

We are proud of our successful track record which is demonstrated in our published studies.

We provide sponsors with FDA compliant analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies, eliminating the need for a dedicated TQT study.

x

Examples of our credentials in TQT and QTc Studies

Food effect on QT interval. Our research has confirmed food impacts cardiac repolarisation by shortening the J-T peak. This can be used in our studies as a non-pharmacological method of proving assay sensitivity. Learn more here.

Sex hormones and the QT Interval. Research funded by Richmond Pharmacology identified a significant influence of estradiol on QTcF suggesting a menstrual cycle could influence the QTc. Learn more here.

Short start-up times of 4-6 weeks, rapid data readout

Our study data is well respected by regulators such as FDA, EMA and PMDA. Our statistical team specialise in statistical analysis concentration effect modelling, reporting, and publishing.

Get in touch today

Why choose Richmond Pharmacology for TQT & QTc Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Low data variability

Our core ECG laboratory provides a centralised system for all our studies.

Read more +

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment.

Read more +

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London.

Read more +

Our in-house cardiac experts include Professor John Camm and Dr Jorg Taubel. Together, they ensure your QTc study is best-in-class. Meet the team.

Latest news

PATIENT WITH RARE BLEEDING DISORDER BECOMES FIRST TO TEST NEW TREATMENT

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event